NCT02551991

Disease Type: Gastrointestinal
Status: Pending

Trial Information

A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Click here for more information

This trial is available at:

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact: